Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma

Trial Profile

Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Benzylguanine (Primary) ; Carmustine (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2017 Primary endpoint (Overall Response Rate) has been met, according to results published in the JAMA Dermatology.
    • 15 Feb 2017 Status changed from active, no longer recruiting to completed, according to results published in the JAMA Dermatology journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top